Skip NavigationSkip to Content
Return Return to Search Results

Opportunities and challenges for the clinical translation of structuredDNAassemblies as gene therapeutic delivery and vaccine vectors

  1. Author:
    Dobrovoskaia, Marina A.
    Bathe, Mark

  2. Author Address

    NCI, Nanotechnol Characterizat Lab, Canc Res Technol Program, Frederick Natl Lab Canc Res, Frederick, MD 21701 USA.MIT, Dept Biol Engn, 77 Massachusetts Ave, Cambridge, MA 02139 USA.
    1. Year: 2020
    2. Date: Jul 15
    3. Epub Date: 2020 07 15
  2. Journal: Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology
  3. WILEY,
  5. Type of Article: Review
  6. Article Number: e1657
  7. ISSN: 1939-5116
  1. Abstract:

    Gene therapeutics including siRNAs, anti-sense oligos, messenger RNAs, and CRISPR ribonucleoprotein complexes offer unmet potential to treat over 7,000 known genetic diseases, as well as cancer, through targeted in vivo modulation of aberrant gene expression and immune cell activation. Compared with viral vectors, nonviral delivery vectors offer controlled immunogenicity and low manufacturing cost, yet suffer from limitations in toxicity, targeting, and transduction efficiency. Structured DNA assemblies fabricated using the principle of scaffolded DNA origami offer a new nonviral delivery vector with intrinsic, yet controllable immunostimulatory properties and virus-like spatial presentation of ligands and immunogens for cell-specific targeting, activation, and control over intracellular trafficking, in addition to low manufacturing cost. However, the relative utilities and limitations of these vectors must clearly be demonstrated in preclinical studies for their clinical potential to be realized. Here, we review the major capabilities, opportunities, and challenges we foresee in translating these next-generation delivery and vaccine vectors to the clinic. This article is categorized under: Therapeutic Approaches and Drug Discovery > Emerging Technologies Biology-Inspired Nanomaterials > Nucleic Acid-Based Structures Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease

    See More

  1. Keywords:

External Sources

  1. View Full Text
  2. DOI: 10.1002/wnan.1657
  3. PMID: 32672007
  4. View record in Web of Science®
  5. WOS: 000548502300001

Library Notes

  1. Fiscal Year: FY2019-2020
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel